ArticleExperimental and therapeutic medicine2017
Naringenin inhibits migration of lung cancer cells via the inhibition of matrix metalloproteinases-2 and -9.
Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 98 citations in OpenAlex.
- Anti-Metastatic Effects ofInternational journal of molecular sciences · 2025Article
- An Updated Review of the Anticancer Mechanisms and Therapeutic Potential of Naringenin.Food science & nutrition · 2025Review
- Article
- Naringenin: A Promising Immunomodulator for Anti-inflammatory, Neuroprotective and Anti-cancer Applications.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2025Review
- A Comprehensive Review of Naringenin, a Promising Phytochemical with Therapeutic Potential.Journal of microbiology and biotechnology · 2024Review
- A Polymethionine Nanoparticle Fluorescent Probe for Sensitive Detection of Naringin and Naringenin.Materials (Basel, Switzerland) · 2024Article
- Integrated Network Pharmacology and Molecular Docking to Explore the Mechanisms of Ningshen Wendan Decoction in the Treatment of Schizophrenia.Alpha psychiatry · 2024Article
- Natural Products as Regulators against Matrix Metalloproteinases for the Treatment of Cancer.Biomedicines · 2024Review
- Dietary Polyphenols Effects on Focal Adhesion Plaques and Metalloproteinases in Cancer Invasiveness.Biomedicines · 2024Review
- Naringenin Nanoformulations for Neurodegenerative Diseases.Current pharmaceutical biotechnology · 2024Review
- Review
- Hyaluronic Acid-Mediated Phenolic Compound Nanodelivery for Cancer Therapy.Pharmaceutics · 2023Review
- Network pharmacology and bioinformatics analysis identifies potential therapeutic targets ofFrontiers in endocrinology · 2023Article
- Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy.Advanced pharmaceutical bulletin · 2023Review
- Copper(II) cation and bathophenanthroline coordination enhance therapeutic effects of naringenin against lung tumor cells.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2022Article
- Regulation of interleukin-6 and matrix metalloproteinases syntheses by bioflavonoids and photobiomodulation in human gingival fibroblasts.Lasers in medical science · 2022Article
- Naringin and Naringenin: Their Mechanisms of Action and the Potential Anticancer Activities.Biomedicines · 2022Review
- Targeting the two-pore channel 2 in cancer progression and metastasis.Exploration of targeted anti-tumor therapy · 2022Review
- Current update on the protective effect of naringin in inflammatory lung diseases.EXCLI journal · 2022Article
- Chiral Flavonoids as Antitumor Agents.Pharmaceuticals (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is among the most common causes of cancer-related mortality. It has a high mortality rate and resistance to chemotherapy due to its high metastatic potential. Naringenin, a bioactive compound identified in several fruits, displays anti-inflammatory and antitumor effects. Furthermore, naringenin mitigates the migration of several human cancer cell types. However, the effects of naringenin on lung cancer remain unclear. The current study investigated the mechanisms of naringenin on the migration of lung cancer A549 cells. The results indicate that significant alteration in A549 cell proliferation was observed in response to naringenin (0-300 µM) treatment for 24 and 48 h. Furthermore, a dose-dependent migration inhibition of A549 in the presence of naringenin was observed by healing and transwell migration assays. In addition, a zymography assay revealed that naringenin exhibited a concentration-dependent inhibition of matrix metalloproteinase (MMP)-2 and -9 activities. Furthermore, naringenin also inhibited the activities of AKT in a dose-dependent manner. These observations indicated that naringenin inhibited the migration of lung cancer A549 cells through several mechanisms, including the inhibition of AKT activities and reduction of MMP-2 and -9 activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.